{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:12Z","timestamp":1792787832600,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018887","name":"Moscow Institute of Physics and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2020-926"],"award-info":[{"award-number":["075-15-2020-926"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2020-926"],"award-info":[{"award-number":["075-15-2020-926"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2020-926"],"award-info":[{"award-number":["075-15-2020-926"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800805"],"award-info":[{"award-number":["81800805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Qingdao Key Research Project","award":["17-3-3-10-nsh and 19-6-1-3-nsh"],"award-info":[{"award-number":["17-3-3-10-nsh and 19-6-1-3-nsh"]}]},{"DOI":"10.13039\/100019558","name":"Qingdao Key Health Discipline Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Overall survival of advanced colorectal cancer (CRC) patients remains poor, and gene expression analysis could potentially complement detection of clinically relevant mutations to personalize CRC treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We performed RNA sequencing of formalin-fixed, paraffin-embedded (FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs according to the efficiency score calculated using target genes expression and molecular pathway activation data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in\n                      <jats:italic>NRAS<\/jats:italic>\n                      , seven others had mutated\n                      <jats:italic>KRAS<\/jats:italic>\n                      gene. Patients were treated by aflibercept, bevacizumab, bortezomib, cabozantinib, cetuximab, crizotinib, denosumab, panitumumab and regorafenib as monotherapy or in combination with chemotherapy, and information on the success of totally 39 lines of therapy was collected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Oncobox drug efficiency score was effective biomarker that could predict treatment outcomes in the experimental cohort (AUC 0.77 for all lines of therapy and 0.91 for the first line after tumor sampling). Separately for bevacizumab, it was effective in the experimental cohort (AUC 0.87) and in 3 independent literature CRC datasets, n\u2009=\u2009107 (AUC 0.84\u20130.94). It also predicted progression-free survival in univariate (Hazard ratio 0.14) and multivariate (Hazard ratio 0.066) analyses. Difference in AUC scores evidences importance of using recent biosamples for the prediction quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results suggest that RNA sequencing analysis of tumor FFPE materials may be helpful for personalizing prescriptions of targeted therapeutics in CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-10177-3","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:03:00Z","timestamp":1667217780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data"],"prefix":"10.1186","volume":"22","author":[{"given":"Maxim","family":"Sorokin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zolotovskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniil","family":"Nikitin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suntsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Poddubskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Glusker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Garazha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Moisseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sekacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Naskhletashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Seryakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Buzdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"10177_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10177_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1590\/s0004-2803.202000000-32","volume":"57","author":"S Aguiar Junior","year":"2020","unstructured":"Aguiar Junior S, Oliveira MM de, Silva DRME, Mello CAL de, Calsavara VF, Curado MP. SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER. Arq Gastroenterol. 2020;57:172\u20137.","journal-title":"Arq Gastroenterol"},{"key":"10177_CR3","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.7314\/APJCP.2015.16.12.4853","volume":"16","author":"S Kumar","year":"2015","unstructured":"Kumar S, Burney IA, Zahid KF, Souza D, Belushi PC, Mufti MAL. TD, et al. Colorectal Cancer Patient Characteristics, Treatment and Survival in Oman\u2013a Single Center Study. Asian Pac J Cancer Prev. 2015;16:4853\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"10177_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.31557\/APJCP.2019.20.1.13","volume":"20","author":"K Maajani","year":"2019","unstructured":"Maajani K, Khodadost M, Fattahi A, Shahrestanaki E, Pirouzi A, Khalili F, et al. Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2019;20:13\u201321.","journal-title":"Asian Pac J Cancer Prev"},{"key":"10177_CR5","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.7314\/APJCP.2014.15.15.6253","volume":"15","author":"AR Baghestani","year":"2014","unstructured":"Baghestani AR, Daneshvar T, Pourhoseingholi MA, Asadzade H. Survival of colorectal cancer patients in the presence of competing-risk. Asian Pac J Cancer Prev. 2014;15:6253\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"10177_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London England). 2014;383:1490\u2013502.","journal-title":"Lancet (London England)"},{"key":"10177_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","volume":"12","author":"MH Cohen","year":"2007","unstructured":"Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12:356\u201361.","journal-title":"Oncologist"},{"key":"10177_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1684\/bdc.2013.1807","volume":"100","author":"T Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 T, Chibaudel B. [Aflibercept (Zaltrap(\u00ae)) approved in metastatic colorectal cancer]. Bull Cancer. 2013;100:1023\u20135.","journal-title":"Bull Cancer"},{"key":"10177_CR9","doi-asserted-by":"publisher","unstructured":"Ettrich TJ, Seufferlein T. Regorafenib. In: Recent Results in Cancer Research. Springer New York LLC. 2018. p.\u00a045\u201356. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_3.","DOI":"10.1007\/978-3-319-91442-8_3"},{"key":"10177_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1517\/14712598.2011.582464","volume":"11","author":"CR Garrett","year":"2011","unstructured":"Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther. 2011;11:937\u201349.","journal-title":"Expert Opin Biol Ther"},{"key":"10177_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","volume":"12","author":"RM Giusti","year":"2007","unstructured":"Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577\u201383.","journal-title":"Oncologist"},{"key":"10177_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.","journal-title":"Signal Transduct Target Ther"},{"key":"10177_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-18722-4","volume-title":"Principles of Cancer Treatment and Anticancer Drug Development","author":"W Link","year":"2019","unstructured":"Link W. Principles of Cancer Treatment and Anticancer Drug Development. Cham: Springer International Publishing; 2019."},{"key":"10177_CR14","doi-asserted-by":"crossref","unstructured":"Afr\u01ces\u00e2nie VA, Marinca MV, Alexa-Stratulat T, Gafton B, P\u01ceduraru M, Adavidoaiei AM, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer-practical implications for the clinician. Radiology and Oncology. 2019;53.","DOI":"10.2478\/raon-2019-0033"},{"key":"10177_CR15","doi-asserted-by":"publisher","unstructured":"Nguyen M, Tipping Smith S, Lam M, Liow E, Davies A, Prenen H, et al. An update on the use of immunotherapy in patients with colorectal cancer. Expert Rev Gastroenterol Hepatol. 2020;:1\u201314. https:\/\/doi.org\/10.1080\/17474124.2021.1845141.","DOI":"10.1080\/17474124.2021.1845141"},{"key":"10177_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.4251\/wjgo.v12.i10.1080","volume":"12","author":"O Kanat","year":"2020","unstructured":"Kanat O, Ertas H, Caner B. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. World J Gastrointest Oncol. 2020;12:1080\u201390. https:\/\/doi.org\/10.4251\/wjgo.v12.i10.1080.","journal-title":"World J Gastrointest Oncol"},{"key":"10177_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.06.009","author":"F Tosi","year":"2020","unstructured":"Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, et al. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020. https:\/\/doi.org\/10.1016\/j.clcc.2020.06.009.","journal-title":"Clin Colorectal Cancer"},{"key":"10177_CR18","doi-asserted-by":"publisher","unstructured":"Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial. ESMO Open. 2020;5. https:\/\/doi.org\/10.1136\/esmoopen-2020-000911.","DOI":"10.1136\/esmoopen-2020-000911"},{"key":"10177_CR19","doi-asserted-by":"publisher","first-page":"vi14","DOI":"10.1093\/annonc\/mdx422.039","volume":"28","author":"G Bruera","year":"2017","unstructured":"Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Giacomo D, Di, et al. Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B\/FOx adding bevacizumab (BEV) to triplet chemotherapy. Ann Oncol. 2017;28:vi14.","journal-title":"Ann Oncol"},{"key":"10177_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/gcc.20854","volume":"50","author":"CP Vaughn","year":"2011","unstructured":"Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50:307\u201312.","journal-title":"Genes Chromosomes Cancer"},{"key":"10177_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/gastro\/goaa022","volume":"8","author":"Z-N Li","year":"2020","unstructured":"Li Z-N, Zhao L, Yu L-F, Wei M-J. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep. 2020;8:192\u2013205.","journal-title":"Gastroenterol Rep"},{"key":"10177_CR22","doi-asserted-by":"publisher","first-page":"e0235490","DOI":"10.1371\/journal.pone.0235490","volume":"15","author":"HE Sanchez-Ibarra","year":"2020","unstructured":"Sanchez-Ibarra HE, Jiang X, Gallegos-Gonzalez EY, Cavazos-Gonz\u00e1lez AC, Chen Y, Morcos F, et al. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study. PLoS ONE. 2020;15:e0235490.","journal-title":"PLoS ONE"},{"key":"10177_CR23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/cam4.2747","volume":"9","author":"LC Bylsma","year":"2020","unstructured":"Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangar\u00e9 L, et al. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med. 2020;9:1044\u201357.","journal-title":"Cancer Med"},{"key":"10177_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.07.010","author":"A Buzdin","year":"2019","unstructured":"Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, et al. RNA sequencing for research and diagnostics in clinical oncology. Semin Cancer Biol. 2019. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.010.","journal-title":"Semin Cancer Biol"},{"key":"10177_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"10177_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver MJ, He YD, van\u2019t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999\u20132009. https:\/\/doi.org\/10.1056\/NEJMoa021967.","journal-title":"N Engl J Med"},{"key":"10177_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.06.003","author":"A Buzdin","year":"2018","unstructured":"Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, et al. Molecular pathway activation \u2013 New type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol. 2018. https:\/\/doi.org\/10.1016\/j.semcancer.2018.06.003.","journal-title":"Semin Cancer Biol"},{"key":"10177_CR28","doi-asserted-by":"publisher","unstructured":"SEQC\/MAQC-III Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Qual Control Consortium. 2014;32. https:\/\/doi.org\/10.1038\/nbt.2957.","DOI":"10.1038\/nbt.2957"},{"key":"10177_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751\u20138. https:\/\/doi.org\/10.1038\/s41591-019-0424-4.","journal-title":"Nat Med"},{"key":"10177_CR30","doi-asserted-by":"publisher","first-page":"117693511983884","DOI":"10.1177\/1176935119838844","volume":"18","author":"A Buzdin","year":"2019","unstructured":"Buzdin A, Sorokin M, Poddubskaya E, Borisov N. High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. Cancer Inf. 2019;18:1176935119838844. https:\/\/doi.org\/10.1177\/1176935119838844.","journal-title":"Cancer Inf"},{"key":"10177_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fmolb.2014.00008","volume":"1","author":"AA Buzdin","year":"2014","unstructured":"Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, et al. The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci. 2014;1:8. https:\/\/doi.org\/10.3389\/fmolb.2014.00008.","journal-title":"Front Mol Biosci"},{"key":"10177_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12859-019-2641-8","volume":"20","author":"N Borisov","year":"2019","unstructured":"Borisov N, Shabalina I, Tkachev V, Sorokin M, Garazha A, Pulin A, et al. Shambhala: a platform-agnostic data harmonizer for gene expression data. BMC Bioinformatics. 2019;20:66. https:\/\/doi.org\/10.1186\/s12859-019-2641-8.","journal-title":"BMC Bioinformatics"},{"key":"10177_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41597-019-0043-4","volume":"6","author":"M Suntsova","year":"2019","unstructured":"Suntsova M, Gaifullin N, Allina D, Reshetun A, Li X, Mendeleeva L, et al. Atlas of RNA sequencing profiles for normal human tissues. Sci data. 2019;6:36. https:\/\/doi.org\/10.1038\/s41597-019-0043-4.","journal-title":"Sci data"},{"key":"10177_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/cancers10100365","volume":"10","author":"M Sorokin","year":"2018","unstructured":"Sorokin M, Kholodenko R, Suntsova M, Malakhova G, Garazha A, Kholodenko I, et al. Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data. Cancers (Basel). 2018;10:365. https:\/\/doi.org\/10.3390\/cancers10100365.","journal-title":"Cancers (Basel)"},{"key":"10177_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-018-0113-x","volume":"7","author":"EV Poddubskaya","year":"2018","unstructured":"Poddubskaya EV, Baranova MP, Allina DO, Smirnov PY, Albert EA, Kirilchev AP, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol. 2018;7:21. https:\/\/doi.org\/10.1186\/s40164-018-0113-x.","journal-title":"Exp Hematol Oncol"},{"key":"10177_CR36","doi-asserted-by":"crossref","unstructured":"Buzdin A, Garazha A, Sorokin M, Glusker A, Aleshin A, Allina D, et al. RNA sequencing analysis for profiling activation of cancer-associated molecular pathways. J Clin Oncol. 2019;37 15_suppl:e13032\u2013e13032.","DOI":"10.1200\/JCO.2019.37.15_suppl.e13032"},{"key":"10177_CR37","doi-asserted-by":"publisher","unstructured":"Borisov N, Sorokin M, Garazha A, Buzdin A. Quantitation of molecular pathway activation using RNA sequencing data. In: Methods in molecular biology (Clifton NJ). 2019. p. In press. https:\/\/doi.org\/10.1007\/978-1-0716-0138-9_15.","DOI":"10.1007\/978-1-0716-0138-9_15"},{"key":"10177_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-0716-0138-9_17","volume-title":"Methods Mol Biol","author":"V Tkachev","year":"2020","unstructured":"Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A. Oncobox method for scoring efficiencies of anticancer drugs based on gene expression data. In: Astakhova K, Bukhari SA, editors. Methods Mol Biol. New York: Springer US; 2020. pp.\u00a0235\u201355. https:\/\/doi.org\/10.1007\/978-1-0716-0138-9_17."},{"key":"10177_CR39","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1200\/JCO.2019.37.15_suppl.e13143","volume":"37 15_suppl","author":"E Poddubskaya","year":"2019","unstructured":"Poddubskaya E, Buzdin A, Garazha A, Sorokin M, Glusker A, Aleshin A, et al. Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors. J Clin Oncol. 2019;37 15_suppl:e13143\u20133.","journal-title":"J Clin Oncol"},{"key":"10177_CR40","doi-asserted-by":"publisher","first-page":"a003434","DOI":"10.1101\/mcs.a003434","volume":"5","author":"EV Poddubskaya","year":"2019","unstructured":"Poddubskaya EV, Baranova MP, Allina DO, Sekacheva MI, Makovskaia LA, Kamashev DE, et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol case Stud. 2019;5:a003434. https:\/\/doi.org\/10.1101\/mcs.a003434.","journal-title":"Cold Spring Harb Mol case Stud"},{"key":"10177_CR41","doi-asserted-by":"publisher","unstructured":"Moisseev A, Albert E, Lubarsky D, Schroeder D, Clark J. Transcriptomic and genomic testing to guide individualized treatment in chemoresistant gastric cancer case. Biomedicines. 2020;8. https:\/\/doi.org\/10.3390\/biomedicines8030067.","DOI":"10.3390\/biomedicines8030067"},{"key":"10177_CR42","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fonc.2019.01026","volume":"9","author":"E Poddubskaya","year":"2019","unstructured":"Poddubskaya E, Bondarenko A, Boroda A, Zotova E, Glusker A, Sletina S, et al. Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Front Oncol. 2019;9:1026. https:\/\/doi.org\/10.3389\/fonc.2019.01026.","journal-title":"Front Oncol"},{"key":"10177_CR43","doi-asserted-by":"crossref","unstructured":"Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol case Stud. 2020;6.","DOI":"10.1101\/mcs.a004945"},{"key":"10177_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1259\/bjr.75.899.750903","volume":"75","author":"V Trillet-Lenoir","year":"2002","unstructured":"Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol. 2002;75:903\u20138.","journal-title":"Br J Radiol"},{"key":"10177_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"key":"10177_CR46","doi-asserted-by":"publisher","first-page":"D472","DOI":"10.1093\/nar\/gkt1102","volume":"42","author":"D Croft","year":"2014","unstructured":"Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014;42:D472\u20137. https:\/\/doi.org\/10.1093\/nar\/gkt1102.","journal-title":"Nucleic Acids Res"},{"key":"10177_CR47","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37 suppl_1","author":"CF Schaefer","year":"2009","unstructured":"Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37 suppl_1:D674\u20139. https:\/\/doi.org\/10.1093\/nar\/gkn653.","journal-title":"Nucleic Acids Res"},{"key":"10177_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"10177_CR49","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1186\/gb-2004-6-1-r2","volume":"6","author":"P Romero","year":"2005","unstructured":"Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 2005;6:R2. https:\/\/doi.org\/10.1186\/gb-2004-6-1-r2.","journal-title":"Genome Biol"},{"key":"10177_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/152791601750294344","volume":"2","author":"D Nishimura","year":"2001","unstructured":"Nishimura D. BioCarta. Biotech Softw Internet Rep. 2001;2:117\u201320. https:\/\/doi.org\/10.1089\/152791601750294344.","journal-title":"Biotech Softw Internet Rep"},{"key":"10177_CR51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Network","year":"2013","unstructured":"Cancer Genome Atlas Research. Network JN, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113\u201320. https:\/\/doi.org\/10.1038\/ng.2764.","journal-title":"Nat Genet"},{"key":"10177_CR52","doi-asserted-by":"crossref","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015 2111. 2015;21:1350\u20136.","DOI":"10.1038\/nm.3967"},{"key":"10177_CR53","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12350-014-9908-2","volume":"21","author":"B George","year":"2014","unstructured":"George B, Seals S, Aban I. Survival analysis and regression models. J Nucl Cardiol. 2014;21:686\u201394.","journal-title":"J Nucl Cardiol"},{"key":"10177_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/2229-3485.86872","volume":"2","author":"R Singh","year":"2011","unstructured":"Singh R, Mukhopadhyay K. Survival analysis in clinical trials: Basics and must know areas. Perspect Clin Res. 2011;2:145\u20138.","journal-title":"Perspect Clin Res"},{"key":"10177_CR55","first-page":"139","volume":"12","author":"AA Buzdin","year":"2021","unstructured":"Buzdin AA, Sorokin M, Borisov NM, Kuzmin D, Gudkov A, Zolotovskaia MA, et al. Algorithmic annotation of functional roles for components of 3044 human molecular pathways. Front Genet. 2021;12:139.","journal-title":"Front Genet"},{"key":"10177_CR56","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","volume":"28","author":"T Shih","year":"2006","unstructured":"Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779\u2013802.","journal-title":"Clin Ther"},{"key":"10177_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajo.2012.04.020","volume":"154","author":"DJ Browning","year":"2012","unstructured":"Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154:222\u20136.","journal-title":"Am J Ophthalmol"},{"key":"10177_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1389557511313040006","volume":"13","author":"T Sharma","year":"2013","unstructured":"Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, et al. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Mini Rev Med Chem. 2013;13:530\u201340.","journal-title":"Mini Rev Med Chem"},{"key":"10177_CR59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"10177_CR60","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41598-017-00839-9","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, Wang L, Zhou Z, Deng Q, Li L, Zhang M, et al. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Sci Rep. 2017;7:682.","journal-title":"Sci Rep"},{"key":"10177_CR61","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298\u2013308.","journal-title":"Mol Cancer Ther"},{"key":"10177_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737140.2017.1344553","volume":"17","author":"A Abdelaziz","year":"2017","unstructured":"Abdelaziz A, Vaishampayan U. Cabozantinib for the treatment of kidney cancer. Expert Rev Anticancer Ther. 2017;17:577\u201384.","journal-title":"Expert Rev Anticancer Ther"},{"key":"10177_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clcc.2015.05.006","volume":"14","author":"MS Lee","year":"2015","unstructured":"Lee MS, Kopetz S. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015;14:203\u201318.","journal-title":"Clin Colorectal Cancer"},{"key":"10177_CR64","first-page":"10-1","volume":"Suppl","author":"RM Goldberg","year":"2005","unstructured":"Goldberg RM. Cetuximab. Nat Rev Drug Discov. 2005;Suppl:10-1.","journal-title":"Nat Rev Drug Discov"},{"key":"10177_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1089\/cbr.2017.2210","volume":"32","author":"F Geng","year":"2017","unstructured":"Geng F, Wang Z, Yin H, Yu J, Cao B. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biother Radiopharm. 2017;32:149\u201360.","journal-title":"Cancer Biother Radiopharm"},{"key":"10177_CR66","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1517\/14656566.2012.688029","volume":"13","author":"PM Forde","year":"2012","unstructured":"Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012;13:1195\u2013201.","journal-title":"Expert Opin Pharmacother"},{"key":"10177_CR67","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","volume":"19","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, Blumenthal GM, Chen H-Y, He K, Patel M, Justice R, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19:e5\u201311.","journal-title":"Oncologist"},{"issue":"1 Suppl 4","key":"10177_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/sonc.2002.31522","volume":"29","author":"DH Lynch","year":"2002","unstructured":"Lynch DH, Yang X-D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29(1 Suppl 4):47\u201350.","journal-title":"Semin Oncol"},{"key":"10177_CR69","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1634\/theoncologist.2008-0254","volume":"14","author":"RM Giusti","year":"2009","unstructured":"Giusti RM, Cohen MH, Keegan P, Pazdur R. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist. 2009;14:284\u201390.","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"10177_CR70","first-page":"1","volume":"17","author":"A Grothey","year":"2019","unstructured":"Grothey A, Prager G, Yoshino T. The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician. Clin Adv Hematol Oncol. 2019;17(Suppl 1):1\u201319.","journal-title":"Clin Adv Hematol Oncol"},{"key":"10177_CR71","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfl245","volume":"21","author":"R Westenfeld","year":"2006","unstructured":"Westenfeld R, Ketteler M, Brandenburg VM. Anti-RANKL therapy\u2013implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density. Nephrol Dial Transplant. 2006;21:2075\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"10177_CR72","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2217\/fon.15.232","volume":"11","author":"S Thosani","year":"2015","unstructured":"Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015;11:2865\u201371.","journal-title":"Future Oncol"},{"key":"10177_CR73","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GTEx Consortium","year":"2013","unstructured":"GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580\u20135.","journal-title":"Nat Genet"},{"key":"10177_CR74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-0716-0138-9_17","volume":"2063","author":"V Tkachev","year":"2020","unstructured":"Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A, Tkachev V, Sorokin M, Garazha A, Borisov NBA, et al. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol. 2020;2063:235\u201355.","journal-title":"Methods Mol Biol"},{"key":"10177_CR75","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3892\/ijo.2018.4626","volume":"54","author":"L Chen","year":"2019","unstructured":"Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non\u2013small cell lung cancer via the NOX4\/ROS\/GLUT1 axis. Int J Oncol. 2019;54:370\u201380. https:\/\/doi.org\/10.3892\/ijo.2018.4626.","journal-title":"Int J Oncol"},{"key":"10177_CR76","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1158\/1078-0432.CCR-17-3431","volume":"24","author":"M Tanioka","year":"2018","unstructured":"Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, et al. Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer. Clin Cancer Res. 2018;24:5292\u2013304. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3431.","journal-title":"Clin Cancer Res"},{"key":"10177_CR77","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00234-018-2021-5","volume":"60","author":"T Liu","year":"2018","unstructured":"Liu T, Cheng G, Kang X, Xi Y, Zhu Y, Wang K, et al. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging. Neuroradiology. 2018;60:693\u2013702. https:\/\/doi.org\/10.1007\/s00234-018-2021-5.","journal-title":"Neuroradiology"},{"key":"10177_CR78","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fonc.2018.00658","volume":"8","author":"MA Zolotovskaia","year":"2018","unstructured":"Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, Buzdin AA. Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Front Oncol. 2018;8:658. https:\/\/doi.org\/10.3389\/fonc.2018.00658.","journal-title":"Front Oncol"},{"key":"10177_CR79","doi-asserted-by":"publisher","first-page":"9022","DOI":"10.18632\/oncotarget.2493","volume":"5","author":"K Lezhnina","year":"2014","unstructured":"Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget. 2014;5:9022\u201332. https:\/\/doi.org\/10.18632\/oncotarget.2493.","journal-title":"Oncotarget"},{"key":"10177_CR80","doi-asserted-by":"crossref","unstructured":"Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, et al. Signaling pathways activation profiles make better markers of cancer than expression of individual genes. Oncotarget. 2014;5:10198\u2013205. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4259415&tool=pmcentrez&rendertype=abstract. Accessed 5 Oct 2015.","DOI":"10.18632\/oncotarget.2548"},{"key":"10177_CR81","unstructured":"Green DM, Swets JA. Signal detection theory and psychophysics. R.E. Krieger Pub. Co; 1974."},{"key":"10177_CR82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/00365519709168308","volume":"57","author":"JC Boyd","year":"1997","unstructured":"Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest. 1997;57:46\u201363.","journal-title":"Scand J Clin Lab Invest"},{"key":"10177_CR83","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1093\/nar\/gni027","volume":"33","author":"J Harbig","year":"2005","unstructured":"Harbig J, Sprinkle R, Enkemann SA. A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res. 2005;33:e31.","journal-title":"Nucleic Acids Res"},{"key":"10177_CR84","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004945","author":"M Sorokin","year":"2020","unstructured":"Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Mol Case Stud. 2020;:mcs.a004945. https:\/\/doi.org\/10.1101\/mcs.a004945.","journal-title":"Mol Case Stud"},{"key":"10177_CR85","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.molonc.2015.03.006","volume":"9","author":"Y Deng","year":"2015","unstructured":"Deng Y, Wang L, Tan S, Kim GP, Dou R, Chen D, et al. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Mol Oncol. 2015;9:1341\u20137.","journal-title":"Mol Oncol"},{"key":"10177_CR86","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-020-17090-y","volume":"11","author":"R Ben-Hamo","year":"2020","unstructured":"Ben-Hamo R, Jacob Berger A, Gavert N, Miller M, Pines G, Oren R, et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nat Commun. 2020;11:3296.","journal-title":"Nat Commun"},{"key":"10177_CR87","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.18632\/oncotarget.3152","volume":"6","author":"P Estevez-Garcia","year":"2015","unstructured":"Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, G\u00f3mez J, Lim\u00f3n ML, et al. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget. 2015;6:6151\u20139.","journal-title":"Oncotarget"},{"key":"10177_CR88","doi-asserted-by":"crossref","unstructured":"Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol case Stud. 2020;6.","DOI":"10.1101\/mcs.a004945"},{"key":"10177_CR89","doi-asserted-by":"publisher","first-page":"10725","DOI":"10.1038\/s41598-020-67842-5","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu J, Cho YB, Hong HK, Wu S, Ebert PJ, Bray SM, et al. Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis. Sci Rep. 2020;10:10725. https:\/\/doi.org\/10.1038\/s41598-020-67842-5.","journal-title":"Sci Rep"},{"key":"10177_CR90","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2407-14-111","volume":"14","author":"G Pentheroudakis","year":"2014","unstructured":"Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, et al. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer. 2014;14:111. https:\/\/doi.org\/10.1186\/1471-2407-14-111.","journal-title":"BMC Cancer"},{"key":"10177_CR91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/ars.2012.4938","volume":"19","author":"D De Zio","year":"2013","unstructured":"De Zio D, Cianfanelli V, Cecconi F. New insights into the link between DNA damage and apoptosis. Antioxid Redox Signal. 2013;19:559\u201371.","journal-title":"Antioxid Redox Signal"},{"key":"10177_CR92","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5603\/FHC.a2016.0018","volume":"54","author":"A Kotulak","year":"2016","unstructured":"Kotulak A, Wronska A, Kobiela J, Godlewski J, Stanislawowski M, Wierzbicki P. Decreased expression of p73 in colorectal cancer. Folia Histochem Cytobiol. 2016;54:166\u201370. https:\/\/doi.org\/10.5603\/FHC.a2016.0018.","journal-title":"Folia Histochem Cytobiol"},{"key":"10177_CR93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41389-020-0193-4","volume":"9","author":"A Uboveja","year":"2020","unstructured":"Uboveja A, Satija YK, Siraj F, Sharma I, Saluja D. p73 \u2013 NAV3 axis plays a critical role in suppression of colon cancer metastasis. Oncogenesis. 2020;9:12. https:\/\/doi.org\/10.1038\/s41389-020-0193-4.","journal-title":"Oncogenesis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10177-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10177-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10177-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:04:33Z","timestamp":1667217873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10177-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10177"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10177-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Vitamed Clinic, Moscow, protocol date 16.10.17.OR. Informed written consents to participate were obtained from all subjects involved in the study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consents for publication were obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MSor, AGar, and AB have a financial relationship with OmicsWay Corp. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1113"}}